Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMBRIA-2 adjuvant camizestrant versus standard endocrine therapy in ER-positive/HER2-negative early breast cancer
2023-504031-41-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 43
01
Overview
Phase 3, randomised, open-label trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Invasive breast cancer-free survival. Planned start Jan 2024; status: authorised.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-504031-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504031-41-00.